Paget's Disease News and Research

RSS

Paget’s disease of the bone is a chronic ailment affecting the skeleton. Sir James Paget described Paget's disease of bone in 1877 and the disease is named after him. This is a rare disease affecting 1% of the population in the United States. It commonly affects the elderly and nearly 3 to 4% of the population over age 50 are affected.

State court jury rules in favor of Merck in FOSAMAX trial

Merck & Co., Inc. today said a state court jury in New Jersey found in its favor in the Rosenberg v. Merck case, rejecting the claims of a woman who blamed her dental and jaw related problems on her FOSAMAX use.

15 Feb 2011

New study reveals measles viral gene plays key role in development of PD

A gene from the measles virus plays a key role in the development of Paget's disease of bone, according to a team of researchers led by the University of Pittsburgh School of Medicine.

18 Jan 2011

TransPharma reports positive results from ViaDerm-Calcitonin Phase 1 trial for musculoskeletal disorders

TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today successful results of a Phase I clinical trial of its self-applied ViaDerm-Calcitonin product for the treatment of musculoskeletal disorders such as osteoarthritis and musculoskeletal pain.

11 Jan 2011

Kanis receives Hamdan Award for Medical Research Excellence in osteoporosis

Professor John A. Kanis is the winner of the 2010 Hamdan Award for Medical Research Excellence in the field of osteoporosis. The prestigious Award honours his outstanding contribution to the development and validation of a widely used fracture risk assessment tool

21 Dec 2010

Merck wins third FOSAMAX bellwether trial

Merck & Co., Inc. today said a federal court jury in New York found in its favor in the Graves v. Merck case, rejecting the claims of a Florida woman who blamed her dental and jaw related problems on her FOSAMAX use. With today's verdict, Merck has won three of the first four bellwether cases in the FOSAMAX litigation.

20 Nov 2010

Novartis announces six-year data of Reclast injection for postmenopausal women with osteoporosis

Novartis announced today that new six-year data reinforce the long-term efficacy and safety profile of once-yearly Reclast (zoledronic acid) injection in postmenopausal women with osteoporosis.The study of more than 1,200 women was presented this weekend at the annual meeting of the American Society for Bone and Mineral Research (ASBMR) in Toronto, ON, Canada.

19 Oct 2010

New data on Merck’s odanacatib for osteoporosis in postmenopausal women presented at 32nd ASBMR

New data on odanacatib, an investigational cathepsin-K (Cat-K) inhibitor in development for the treatment of osteoporosis in postmenopausal women, were presented at the 32nd Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) in Toronto, Canada.

19 Oct 2010

Six-year data of reinforces efficacy and safety of Reclast injection in postmenopausal women with osteoporosis

Novartis announced today that new six-year data reinforce the long-term efficacy and safety profile of once-yearly Reclast (zoledronic acid) injection in postmenopausal women with osteoporosis. The study of more than 1,200 women was presented this weekend at the annual meeting of the American Society for Bone and Mineral Research (ASBMR) in Toronto, ON, Canada.

18 Oct 2010

$FDA warns of risk of atypical thigh bone fracture in patients taking bisphosphonates$

FDA warns of risk of atypical thigh bone fracture in patients taking bisphosphonates

The U.S. Food and Drug Administration today warned patients and health care providers about the possible risk of atypical thigh bone (femoral) fracture in patients who take bisphosphonates, a class of drugs used to prevent and treat osteoporosis. A labeling change and Medication Guide will reflect this risk. Bisphosphonates inhibit the loss of bone mass in people with osteoporosis.

14 Oct 2010

Merck to appeal against jury verdict in retrial of federal FOSAMAX case

Merck & Co., Inc. today said it will appeal a decision by the U.S. District Court for the Southern District of New York that reduced the jury verdict from $8 million to $1.5 million but denied Merck's request for judgment in its favor or a new trial in the case of Boles v. Merck, a retrial of a federal FOSAMAX case.

5 Oct 2010

$Bisphosphonates drug may lead to atypical femur fractures in osteoporosis patients: Report$

Bisphosphonates drug may lead to atypical femur fractures in osteoporosis patients: Report

A widely prescribed class of drugs is highly effective in reducing common bone fractures in people with osteoporosis, but an expert panel announced today that these same drugs - when used long term - may be related to unusual but serious fractures of the thigh bone.

14 Sep 2010

Merck challenges New York jury decision in federal FOSAMAX retrial

Merck & Co., Inc. today said it is challenging the decision returned by a New York jury in the retrial of a federal FOSAMAX case, Boles v. Merck. This case was the Plaintiffs' Steering Committee's top choice to take to trial and involved a Florida woman who blamed her dental and jaw problems on FOSAMAX. The first case to reach a verdict, Maley v. Merck, resulted in a defense verdict for Merck on May 5, 2010.

28 Jun 2010

Scientists discover three genes linked to development of Paget's disease

Scientists have discovered three genes linked to the development of Paget's disease, a painful bone condition that affects up to one million people in the UK.

3 May 2010

Sagent Pharmaceuticals introduces pamidronate disodium injection in single-dose vials

Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced that it has launched pamidronate disodium injection in single-dose vials containing 30 mg per 10 mL and 90 mg per 10 mL. Pamidronate disodium injection, the generic alternative of Novartis Pharmaceutical Company's Aredia®, is a bone resorption inhibitor. The 2008 U.S. market for pamidronate disodium approximated $17 million, according to IMS data.

20 Jan 2010

Extended treatment with active ingredient increases bone volume and calcium content

Genta Incorporated today announced publication of two scientific studies that test the active ingredient in Genta’s program to develop orally available gallium-containing compounds and the Company’s marketed product, Ganite® (gallium nitrate for injection).

13 Jan 2010

Emisphere's oral salmon calcitonin product addresses persistent musculoskeletal pain

Emisphere Technologies, Inc. today announced a meta-analysis published in the December 2009 edition of Rheumatology Reports examining independent evidence of the analgesic action of the hormone calcitonin. This publication restates the potential of calcitonin in filling a significant unmet need for alternative treatments for persistent musculoskeletal pain.

22 Dec 2009

Mutant ATPase blocks autophagy partway and causes multi-tissue degenerative disease

It's important to finish what you start, say Jeong-Sun Ju and researchers from Washington University School of Medicine, St. Louis. In the December 14, 2009 issue of the Journal of Cell Biology (www.jcb.org), Ju et al. reveal how a mutant ATPase blocks autophagy partway through to cause a multi-tissue degenerative disease.

15 Dec 2009

U.S. Court rules in Merck's favor in Flemings case involving FOSAMAX

Merck said today that U.S. District Court Judge John F. Keenan granted summary judgment in Merck's favor in Flemings v. Merck. Flemings is the second of three cases involving FOSAMAX (alendronate sodium) designated by the federal MDL court as a bellwether trial case.

24 Nov 2009

Genta announces financial results for the third quarter of 2009, reduces workforce to cut payroll costs

Genta Incorporated today announced financial results for the quarter and nine months ended September 30, 2009. The Company also announced a restructuring, reduction in workforce, and re-ordering of clinical development priorities.

16 Nov 2009

FDA approves Reclast (zoledronic acid) for osteoporosis in postmenopausal women

Reclast (zoledronic acid) Injection has been approved by the US Food and Drug Administration (FDA) as the first and only therapy to prevent postmenopausal osteoporosis for two years with a single dose. Reclast is already approved as a once-yearly infusion for the treatment of postmenopausal osteoporosis.

1 Jun 2009